Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal


Classification: C!

Drug products: Janumet®, Januvia®, Sitagliptin Glenmark, Sitagliptin Krka, Sitagliptin Mylan, Sitagliptin Orion, Sitagliptin Sandoz, Sitagliptin STADA, Sitagliptin SUN, Sitagliptin Zentiva, Sitagliptin/Metformin Glenmark, Sitagliptin/Metformin Krka, Sitagliptin/Metformin Sandoz, Sitagliptin/Metformin Zentiva, Velmetia®, Xelevia®

ATC code: A10BD07, A10BH01

Substances: sitagliptin, sitagliptin fumarate, sitagliptin hydrochloride monohydrate, sitagliptin phosphate, sitagliptin phosphate monohydrate


In a large cohort study assessing the effect of sitagliptin treatment on cardiovascular (CV) outcomes, women had a lower risk compared to men.

Women had a higher risk of hypoglycemia compared to men in a clinical study in patients treated with sitagliptin.

Additional information

Studies indicate that men in the early middle age have a higher prevalence of type 2 diabetes mellitus compared with women in the same age group [1]. In Sweden, the age-standardized prevalence of pharmacologically and non-pharmacologically treated diabetes was 56% for men and 39% for women in 2012 [2].

Pharmacokinetics and dosing

Clinical studies have shown no pharmacokinetic differences between men and women of single- or multiple-dose sitagliptin [3, 4]. According to the original manufacturer, no clinically relevant pharmacokinetic sex differences have been shown [5].

In a Japanese retrospective cohort study (in total 87 678 patients), dose levels of sitagliptin were compared before and after the safety alert on the risk of serious hypoglycemic events with the combination sitagliptin and high-dose sulfonylureas. Women were prescribed lower mean daily doses of sitagliptin both before and after the safety alert (before; women : 59.6 ± 21.8 mg, men: 63.4 ± 24.4 mg, after; women: 57.2 ± 20.1 mg, men: 61.6 ± 23.7 mg) [6]. However, the original manufacturer does not recommend any dose adjustment based on patient’s sex [5].


 A placebo-controlled trial assessed the effect of sitagliptin treatment on cardiovascular (CV) outcomes in a prospective study in patients with type 2 diabetes and atherosclerotic vascular disease (10 374 men, 4297 women), the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) [7]. Sex differences in management and outcomes of the TECOS trial were analyzed [8]. The primary composite outcome of CV death, myocardial infarction, stroke, or hospitalization for unstable angina occurred in 418 women (9.7%) and 1272 men (12.3%; 3.48 vs 4.38 events/100 participant-years, adjusted HR 0.64, 95% CI 0.55-0.74). Women also had a significantly lower risk of secondary CV outcomes and all-cause death (1.58 vs 1.74 events/100 participant-years [adjusted HR 0.55, 95% CI 0.42-0.71) and all-cause death (2.18 vs 2.56 events/100 participant-years, adjusted HR 0.54, 95% CI 0.43-0.67) [8]. Differences in baseline characteristics of patients enrolled in the TECOS trial [7] was examined (10416 men, 4308 women). The prespecified clinical target goals in baseline characteristics were chosen to reflect those consistent with international guidelines at the time of the trial’s inception. The results showed that women were consistently less likely to reach the prespecified treatment target goals assessed at the time of study enrollment (SBP<140 mmHg, DBP<80 mmHg, LDL cholesterol <2.6 mmol/L, aspirin use, and statin use), with the exception of non-smoking status [9].

The effect on metabolic control and on CV risk evolution obtained by “add-on” persistent sitagliptin treatment (100 mg once daily) in a cohort of Italian participants with type 2 diabetes was assessed using the UK Prospective Diabetes Study (UKPDS) Risk Engine (RE). Analysis of sex differences in CV risk evolution evaluated by UKPDS RE (106 men, 64 women) showed a significantly lower CV risk in women (1.33 in men vs 1.12 in women in UKPDS after 48 months) [10].

A post-hoc analysis of pooled data from seven sitagliptin phase II and III clinical trials exploring the factors associated with the glucose-lowering efficacy of sitagliptin treatment in Japanese patients with type 2 diabetes (698 men, 370 women) showed no association between HbA1c changes and patient’s sex [11].

Adverse effects

A study evaluated the relative risk of hypoglycemic events in patients (691 men, 481 women) treated with sitagliptin or glipizide after adjusting for the most recently measured HbA1c value. The adjusted hazard ratio for women on either of the two studied drugs was 2.05, indicating that women had a twofold increase in risk of experiencing confirmed hypoglycemia relative to men. In multivariate analysis, female sex was one of the factors associated with a higher risk of hypoglycemia [12].

The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors was evaluated in an observational study from Taiwan. The subgroup analysis showed a lower risk of incident atrial fibrillation for SGLT2 inhibitors (9091 men, 6515 women) versus DPP-4 inhibitors (6911 men, 5472 women) in women compared to men with type 2 diabetes (HR men 0.51, HR women 0.70, p interaction =0.10) [13].

The fracture incidence among participants (10374 men, 4297 women) in the TECOS trial [7] was examined [14]. Although sitagliptin, compared with placebo, was not associated with a higher fracture risk (HR 1.03), adjusted analyses showed a significantly independently increased fracture risk in women (HR 1.95) [14].

A study with data on sitagliptin ever and never users (93858 men, 77860 women) derived from the Taiwan’s National Health Insurance evaluated the risk of heart failure hospitalization. Male sex was significantly associated with a higher risk of heart failure hospitalization in patients ever treated with sitagliptin (HR 1.033 men vs women) [15].

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Other information (utelämna om inte tillämpligt)

Data from the Italian Medicines Agency (AIFA) Monitoring Registry on drug utilization, safety and effectiveness of exenatide, sitagliptin, and vildagliptin showed that the risk of treatment discontinuation of sitagliptin was lower in men than women (20446 men, 18365 women). The authors discuss the relationship between discontinuation rates and adverse effects such as hypoglycemia [16].

An Italian multicenter, case-control, retrospective observational study investigated the effect of sitagliptin as an add-on treatment to standard care insulin administration in patients with type 2 diabetes who were hospitalized with COVID-19 (238 men, 100 women). A time to clinical endpoint subgroup analysis comparing men versus women in the sitagliptin-treated group as compared with those in the standard-of-care group did not show any difference in the clinical outcomes within the group of treatment (HR men 0.44, HR women 0.42) [17].

Updated: 2022-11-09

Date of litterature search: 2021-05-26


  1. Gale EA, Gillespie KM. Diabetes and gender. Diabetologia. 2001;44(1):3-15. PubMed
  2. Jansson SP, Fall K, Brus O, Magnuson A, Wändell P, Östgren CJ et al. Prevalence and incidence of diabetes mellitus: a nationwide population-based pharmaco-epidemiological study in Sweden. Diabet Med. 2015;32(10):1319-28. PubMed
  3. Lyseng-Williamson KA. Sitagliptin. Drugs. 2007;67:587-97. PubMed
  4. Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012;51:501-14. PubMed
  5. Januvia (sitagliptin). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2021-02-23, cited 2021-05-26]
  6. Sato D, Sato Y, Masuda S, Kimura H. Impact of the sitagliptin alert on prescription of oral antihyperglycemic drugs in Japan. Int J Clin Pharm. 2012;34:917-24. PubMed
  7. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373(3):232-42. PubMed
  8. Alfredsson J, Green JB, Stevens SR, Reed SD, Armstrong PW, Angelyn Bethel M, Engel SS, McGuire DK, Van de Werf F, Hramiak I, White HD, Peterson ED, Holman RR; TECOS Study Group. Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS. Diabetes Obes Metab. 2018;20(10):2379-2388. länk
  9. Bethel MA, Green JB, Milton J, Tajar A, Engel SS, Califf RM et al. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Obes Metab. 2015;17(4):395-402. PubMed
  10. Buonaiuto G, De Mori V, Braus A, Balini A, Berzi D, Carpinteri R, Forloni F, Meregalli G, Ronco GL, Bossi AC. PERS&O (PERsistent Sitagliptin treatment & Outcomes): observational retrospective study on cardiovascular risk evolution in patients with type 2 diabetes on persistent sitagliptin treatment. BMJ Open Diabetes Care. 2016;4(1):0. länk
  11. Tajima N, Eiki JI, Okamoto T, Okuyama K, Kawashima M, Engel SS. Factors associated with the glucose-lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials. J Diabetes Investig. 2020;11(3):640-646. PubMed
  12. Krobot KJ, Ferrante SA, Davies MJ, Seck T, Meininger GE, Williams-Herman D et al. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value. Curr Med Res Opin. 2012;28:1281-7. PubMed
  13. Ling AW, Chan CC, Chen SW, Kao YW, Huang CY, Chan YH, Chu PH. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. Cardiovasc Diabetol. 2020;19(1):188. länk
  14. Josse RG, Majumdar SR, Zheng Y, Adler A, Bethel MA, Buse JB, Green JB, Kaufman KD, Rodbard HW, Tankova T, Westerhout CM, Peterson ED, Holman RR, Armstrong PW; TECOS Study Group. Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial. Diabetes Obes Metab. 2017;19(1):78-86. länk
  15. Tseng CH. Sitagliptin and heart failure hospitalization in patients with type 2 diabetes. Oncotarget. 2016;7(38):62687-62696. länk
  16. Montilla S, Marchesini G, Sammarco A, Trotta MP, Siviero PD, Tomino C et al. Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry. Nutr Metab Cardiovasc Dis. 2014;24(12):1346-53. PubMed
  17. Solerte SB, D'Addio F, Trevisan R, Lovati E, Rossi A, Pastore I, Dell'Acqua M, Ippolito E, Scaranna C, Bellante R, Galliani S, Dodesini AR, Lepore G, Geni F, Fiorina RM, Catena E, Corsico A, Colombo R, Mirani M, De Riva C, Oleandri SE, Abdi R, Bonventre JV, Rusconi S, Folli F, Di Sabatino A, Zuccotti G, Galli M, Fiorina P. Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study. Diabetes Care. 2020;43(12):2999-3006. länk
  18. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2020 [cited 2021-03-10.] länk

Authors: Diana Rydberg, Linnéa Karlsson Lind

Reviewed by: Alan Fotoohi

Approved by: Karin Schenck-Gustafsson